Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (WO2019005437) A MELANOGENESIS INHIBITOR COMPOSITION
Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

We Claim:

1. A melanogenesis inhibitor combination, comprising:

a combination of

a (Z)-N-(4-hydroxybenzylidene)propan-2-amine oxide; and a comp


(I) wherein R1 and R2 are independently selected from a hydrogen atom and an acyl group having 3 to 20 carbon atoms;

wherein the combination is dispersed in a dermatologically acceptable carrier.

2. The melanogenesis inhibitor combination of claim 1, wherein the compound of formula I is selected from the group consisting of kojic acid, kojic acid monobutyrate, kojic acid monocaprate, kojic acid monopalmitate, kojic acid monostearate, kojic acid monocinnamoate, kojic acid monobenzoate, kojic acid dibutyrate, kojic acid dipalmitate, kojic acid distearate, kojic acid dioleate.

3. The melanogenesis inhibitor combination of claim 2, wherein R1 is an -OH group.

4. The melanogenesis inhibitor combination of claim 3, wherein the combination contains 0.001 to < 0.01 wt% of pHBz-IPHA.

5. The melanogenesis inhibitor combination of claim 1, wherein the compound of formula I is kojic acid.

6. The melanogenesis inhibitor combination of claim 4, wherein the compound of formula I is kojic acid.

7. The melanogenesis inhibitor combination of claim 1, wherein the dermatologically acceptable carrier is selected from the group consisting of at least one of an emulsion, a cream, an aqueous solution, an oil, an ointment, a paste, a gel, a lotion, a milk, a foam, a suspension and a powder.

8. A method of inhibiting melanogenesis activity and melanin production in an animal having skin to improve appearance of the skin, comprising topically applying a melanogenesis inhibitor combination of claim 1 to the skin.

9. The method of claim 8, wherein the melanogenesis inhibitor combination topically applied to the skin contains 0.001 to < 0.01 wt% of pHBz-IPHA.

10. The method of claim 8, wherein the melanogenesis inhibitor combination topically applied to the skin contains 0.001 to < 0.01 wt% of pHBz-IPHA and kojic acid.